GlassScriptPhysician profile
Stephen Grabelsky
NPI 1366490781
$9,361.42
in general payments reported to CMS, 2019-2025
41 companies · $581 in 2025
The $581 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,887 · 2020: $264 · 2021: $106 · 2022: $689 · 2023: $469 · 2024: $366 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $5,321.94 | 2019 | |
| Beigene USA, INC. | $544.40 | 2022-2024 | Brukinsa |
| Janssen Biotech, INC. | $483.47 | 2019-2025 | Erleada, Balversa, Akeega |
| Pfizer INC. | $323.34 | 2019-2025 | |
| Astellas Pharma US INC | $312.19 | 2019-2023 | Padcev, Xtandi |
| Novartis Pharmaceuticals Corporation | $290.61 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $289.71 | 2019-2025 | Opdivo, Reblozyl, Krazati |
| Genentech USA, INC. | $166.91 | 2019-2025 | Tecentriq |
| Astrazeneca Pharmaceuticals LP | $152.05 | 2019-2025 | Lynparza |
| Merck Sharp & Dohme LLC | $137.08 | 2019-2025 | Lynparza, Keytruda |
| Abbvie INC. | $129.10 | 2019-2025 | |
| Array Biopharma INC | $101.11 | 2025 | Braftovi, Mektovi, Tukysa |
| Seagen INC. | $100.67 | 2019-2023 | Tivdak, Padcev |
| Glaxosmithkline, LLC. | $84.13 | 2023-2025 | Jemperli, Zejula, Shingrix |
| Celgene Corporation | $77.75 | 2019-2024 | Pomalyst |
Show all 39 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Grabelsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.